Case Report on Renal Failure Reversal in Lambda Chain Multiple Myeloma with Bortezomib and Dexamethasone
Renal failure (RF) reversal in multiple myeloma (MM) is associated with an improved prognosis. Light chain myeloma, serum creatinine (SCr) > 4 mg/dL, extensive proteinuria, early infections, and certain renal biopsy findings are associated with lower rates of RF reversal. Our patient is a 67-year...
Saved in:
Main Authors: | Bhanu K. Patibandla, Akshita Narra, Ahmad A. Alwassia, Anthony Bartley, Gurprataap S. Sandhu, James Rooney, Robert M. Black |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Case Reports in Nephrology |
Online Access: | http://dx.doi.org/10.1155/2014/940171 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment of Coexisting Chronic Neutrophilic Leukemia and Light Chain Multiple Myeloma with Hydroxyurea, Bortezomib, and Dexamethasone
by: Evelyn Taiwo, et al.
Published: (2014-01-01) -
Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
by: Yin-Che Wang, et al.
Published: (2025-12-01) -
Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Claudio Cerchione, et al.
Published: (2016-01-01) -
Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
by: Juan M. Cano-Calderón, et al.
Published: (2025-01-01) -
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01)